Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoTSE:4519 -2.15%96 Current Ratio is 4.70 as of Mar. 2026, which is 0% below its 10-year median of 4.72. GuruFocus rates TSE:4519 with a GF Score™ of 96/100 and a GF Value™ of 円7,735.19 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,000 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 84.1% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Chugai Pharmaceutical Co's current ratio for the quarter that ended in Mar. 2026 was 4.70.
Chugai Pharmaceutical Co has a current ratio of 4.70. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Chugai Pharmaceutical Co's Current Ratio or its related term are showing as below:
TSE:4519'
s Current Ratio Range Over the Past 10 Years
Min: 3.15 Med: 4.72 Max: 7.28
Current: 4.7
During the past 13 years, Chugai Pharmaceutical Co's highest Current Ratio was 7.28. The lowest was 3.15. And the median was 4.72.
TSE:4519's Current Ratio is ranked better than 84.1% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs TSE:4519: 4.70
Chugai Pharmaceutical Co (TSE:4519) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Chugai Pharmaceutical Co Current Ratio Related Terms
Chugai Pharmaceutical Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4519 vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (TSE:4519) has a Current Ratio of 4.70 as of Mar. 2026. This is near median its historical median of 4.72. Over the past decade, Chugai Pharmaceutical Co's Current Ratio has ranged from 3.15 to 7.28. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #159 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 15.9%.
Is Chugai Pharmaceutical Co's Current Ratio too high?
Chugai Pharmaceutical Co's current Current Ratio of 4.70 is near median its 10-year median of 4.72. Over the past 10 years, this metric has ranged from a low of 3.15 to a high of 7.28. The Drug Manufacturers industry median Current Ratio is 2.00. Chugai Pharmaceutical Co's value of 4.70 is 135% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #159 out of 1000 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #159 out of 1000 companies for Current Ratio. This places Chugai Pharmaceutical Co in the top 16% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Chugai Pharmaceutical Co's value of 4.70 is 135% above this benchmark. Historically, Chugai Pharmaceutical Co's own Current Ratio has ranged from 3.15 to 7.28 over the past decade. While the company's 10-year median is 4.72 vs. the industry median of 2.00, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Current Ratio of 4.70 is 135% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Current Ratio is 4.70, which is near median its own 10-year median of 4.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (TSE:4519) is currently considered Fairly Valued. The stock's GF Value™ is 円7,735.19, compared to a current price of 円7,230.00 — trading 6.5% below its estimated fair value. The current Current Ratio is 4.70, which is near median its 10-year median of 4.72 and 135% above the Drug Manufacturers industry median of 2.00. Chugai Pharmaceutical Co's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Chugai Pharmaceutical Co (TSE:4519), the current Current Ratio is 4.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円7,230.00 is trading 6.5% below its estimated GF Value™ of 円7,735.19.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4519:
Current Ratio: 4.70 (near median its 10-year median of 4.72)
GF Value™: 円7,735.19 vs. price of 円7,230.00 (6.5% below fair value)
Industry Position: 135% above the Drug Manufacturers median (#159 of 1000)
No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
96GF Score
Get the complete analysis for TSE:4519
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4519 has been successfully added to your 
